Trial Profile
A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2015
Price :
$35
*
At a glance
- Drugs Gildeuretinol (Primary)
- Indications Age-related macular degeneration; Retinal dystrophies; Stargardt disease
- Focus Adverse reactions
- Sponsors Alkeus Pharmaceuticals
- 17 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 23 Sep 2014 New trial record